Envista recently entered into a definitive agreement to acquire the Osteogenics Biomedical Business, which includes Osteogenics Biomedical Inc, Allotech LLC and OBI Biologics.
Osteogenics develops regenerative solutions for periodontists, oral and maxillofacial surgeons, and clinicians involved in implant dentistry, according to a press release. The transaction is subject to customary regulatory approvals and expected to close in the third quarter.
Osteogenics offers a complete line of bone grafting products, primarily under the Cytoplast brand.
"Increasing our capabilities in regenerative solutions is consistent with our intention to digitize, personalize and democratize oral care,” Envista CEO Amir Aghdaei said, according to the release. “Osteogenics is a recognized pioneer in membrane technologies used in dental bone grafting procedures. They are a trusted brand and have a proven track record of growth. We are excited to welcome the Osteogenics team to Envista."
View Full Press Release
ENVISTA TO ACQUIRE OSTEOGENICS BIOMEDICAL BUSINESS
BREA, Calif.-- Envista Holdings Corporation (NYSE: NVST) ("Envista") today announced it has entered into a definitive agreement to acquire Osteogenics Biomedical Inc, Allotech LLC and OBI Biologics, Inc (together "Osteogenics"). The transaction is subject to customary regulatory approvals and expected to close in the Third Quarter.
Osteogenics is a leader in the development of innovative regenerative solutions for periodontists, oral & maxillofacial surgeons, and clinicians involved in implant dentistry throughout the world. Primarily sold under the CytoplastTM brand name, Osteogenics offers a complete line of bone grafting products. Bone grafting and regenerative therapies are often a critical step in implant based tooth replacements. By improving bone stability, regenerative solutions support better clinical outcomes for more patients.
Envista's CEO Amir Aghdaei said, "Increasing our capabilities in regenerative solutions is consistent with our intention to digitize, personalize, and democratize oral care. Osteogenics is a recognized pioneer in membrane technologies used in dental bone grafting procedures. They are a trusted brand and have a proven track record of growth. We are excited to welcome the Osteogenics team to Envista."
The transaction is not subject to a financing condition or shareholder vote.